Publication:
Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.

Simple item page
dc.contributor.authorSimsek, MELİH
dc.contributor.authorAliyev, Altay
dc.contributor.authorBaydas, Tuba
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorDemir, Tarik
dc.contributor.authorShbair, Abdallah Tm
dc.contributor.authorSeker, Mesut
dc.contributor.authorTurk, H Mehmet
dc.contributor.institutionauthorŞİMŞEK, MELİH
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2022-09-06T20:59:14Z
dc.date.available2022-09-06T20:59:14Z
dc.date.issued2022-08-19T00:00:00Z
dc.description.abstractThe prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features of breast cancer patients with brain metastases and to determine the risk factors and survival outcomes associated with brain metastasis. This is a single-center, retrospective, cross-sectional study. A total number of 127 patients diagnosed with breast cancer and who developed brain metastasis between January 2011 and March 2021 were retrospectively analyzed. The survival and clinicopathological data of these patients according to 4 biological subtypes were evaluated (luminal A, luminal B, HER-2 overexpressing, and triple-negative). The median overall survival for all patients was 45.6 months. The median time from the diagnosis of breast cancer to the occurrence of brain metastasis was 29.7 months, and the median survival time after brain metastasis was 7.2 months. The time from the diagnosis of breast cancer to brain metastasis development was significantly shorter in HER-2 overexpressing and triple-negative subtypes than in luminal A and B subtypes. The median time from breast cancer diagnosis to brain metastasis was 33.5 months in luminal A, 40.6 months in luminal B, 16.8 months in HER-2 overexpressing, and 22.8 months in the triple-negative groups (p=0.003). We found the worst median survival after brain metastasis in the triple-negative group with 3.5 months. Early and close surveillance of high-risk patients may help early diagnosis of brain metastasis and may provide to perform effective treatments leading to longer overall survival times for this patient population.
dc.identifier.citationSimsek M., Aliyev A., Baydas T., Besiroglu M., Demir T., Shbair A. T. , Seker M., Turk H. M. , -Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.-, The breast journal, cilt.2022, ss.5763810, 2022
dc.identifier.doi10.1155/2022/5763810
dc.identifier.pubmed36051468
dc.identifier.scopus85137095179
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30953
dc.identifier.wosWOS:000848413900001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleBreast Cancer Patients with Brain Metastases: A Cross-Sectional Study.
dc.typeArticle
dspace.entity.typePublication
local.avesis.id377c234a-ef2d-4ee1-aaa5-f3a53bedd697
local.publication.isinternational1
relation.isAuthorOfPublication037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery037fbf0b-fefb-4173-9f93-478d96e2926f
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Breast Cancer Patients with Brain Metastases A Cross-Sectional Study.pdf
Size:
622.82 KB
Format:
Adobe Portable Document Format
Download
Collections
Yayınlar - Eserler